Literature DB >> 16621737

Development of an HPLC method for the determination of nifedipine in human plasma by solid-phase extraction.

Dragica Zendelovska1, Suzana Simeska, Olgica Sibinovska, Elena Kostova, Kalina Milosevska, Krume Jakovski, Emilija Jovanovska, Igor Kikerkov, Jasmina Trojacanec, Dimce Zafirov.   

Abstract

Nifedipine, a dihydropyridine calcium channel antagonist, is widely used in the treatment of hypertension and other cardiovascular disorders. A selective, sensitive and accurate high-performance liquid chromatographic method has been developed, validated and applied for determination of nifedipine in human plasma samples. A series of studies were conducted in order to investigate the effects of mobile phase composition, buffer concentration, mobile phase pH and concentration of organic modifiers, and to develop a convenient and easy-to-use method for quantitative analysis of nifedipine. The method involves solid-phase extraction on C18 cartridges. The chromatographic separation was accomplished on a Lichrocart Lichrospher 60 RP selectB column with a mobile phase composed of 0.020 mol/L KH2PO4 (pH 4.8) and acetonitrile (42:58, v/v). UV detection was set at 240 nm. The calibration curve was linear in the concentration range of 5.0-200.0 ng/mL for nifedipine in plasma and the limit of quantification was 5.0 ng/mL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621737     DOI: 10.1016/j.jchromb.2006.03.048

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Bioequivalence of nifedipine softgel and capsule in healthy Chinese volunteers by liquid chromatography-mass spectrometry.

Authors:  Jing Zhang; Hao-Jing Song; Fan-Long Bu; Chun-Min Wei; Gui-Yan Yuan; Xiao-Yan Liu; Ben-Jie Wang; Rui-Chen Guo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

2.  Development and validation of LC/MS/MS method for the simultaneous determination of montelukast, gliclazide, and nifedipine and its application to a pharmacokinetic study.

Authors:  Essam Ezzeldin; Nisreen F Abo-Talib; Marwa H Tammam; Abdelaaty A Shahat
Journal:  Chem Cent J       Date:  2014-03-11       Impact factor: 4.215

3.  Investigation of the in vitro performance difference of drug-Soluplus® and drug-PEG 6000 dispersions when prepared using spray drying or lyophilization.

Authors:  Mohammad A Altamimi; Steven H Neau
Journal:  Saudi Pharm J       Date:  2016-09-30       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.